Immuno-Oncology | Specialty

TMB as a Predictive Biomarker in NSCLC

October 10th 2018

Combining Chemotherapy & Immunotherapy in Squamous NSCLC

October 10th 2018

Immunotherapy + Chemotherapy in Nonsquamous NSCLC

October 10th 2018

Upfront PD-1 Inhibitor Monotherapy in Advanced NSCLC

October 10th 2018

Practical Application of Recent Clinical Data for Immunotherapy in NSCLC

October 10th 2018

Resistance to PD-1 Checkpoint Blockade

October 9th 2018

Michelle Krogsgaard, PhD, associate professor, Department of Pathology, NYU Langone's Perlmutter Cancer Center, discusses mechanisms of resistance to PD-1 checkpoint blockade.

Persistence Paved the Path of Discovery for an Immunotherapy Pioneer

October 8th 2018

Thomas F. Gajewski, MD, PhD, has made inroads in the field of cancer immunotherapy, most notably discovering the connections between the microbiome and clinical outcomes—findings that will enable the creation of microbiota-modulating interventions to improve outcomes in patients undergoing cancer treatments.

Dr. Spigel Reflects on the PACIFIC Study in NSCLC

October 5th 2018

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, reflects on the results of the PACIFIC trial in patients with non–small cell lung cancer.

TILs Show Growing Potential as Novel Immunotherapy

October 5th 2018

Although checkpoint-blocking antibodies dominate the anticancer immunotherapy field today, researchers are increasingly exploring the potential to leverage growing knowledge about tumor-infiltrating lymphocytes to develop new drugs.

Allison Reflects on a Career in Immunology, Nobel Prize

October 4th 2018

James P. Allison, PhD, reflects on his research in immunology, the impact it has had on patients with cancer, and where the field is headed.

Immunotherapy Continues to Be Integrated in Metastatic Bladder Cancer

October 4th 2018

Peter O’Donnell, MD, discusses the integration of immunotherapy in the treatment paradigm of advanced bladder cancer and its potential role as combination therapy.

A New Front Line Is Taking Shape in Metastatic Renal Cell Carcinoma

October 3rd 2018

The dismal prognosis for patients with metastatic renal cell carcinoma has fueled an earnest quest for more effective treatments, culminating in a better understanding of the disease and regulatory approval of several new drugs and therapeutic combinations.

Dr. Allison Discusses the Future of Immunotherapy in Cancer Care

October 2nd 2018

James P. Allison, PhD, chair of Immunology and executive director of the Immunotherapy Platform at The University of Texas MD Anderson Cancer Center, and a recipient of the 2018 Nobel Prize in Physiology or Medicine, discusses the future of immunotherapy in the treatment of patients with cancer.

Novel Agent Stimulates T-Cell Activity in Tumor Microenvironment

October 2nd 2018

Investigators are hopeful that M7824, a bifunctional fusion protein that inhibits the PD-L1 and TGF-β pathways, will improve immune system responses across tumor types.

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers

October 2nd 2018

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers.

Allison, Honjo Win Nobel Prize for Research on Immune Checkpoints

October 1st 2018

Immunotherapy pioneers James P. Allison, PhD, and Tasuku Honjo, MD, PhD, have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Weber Highlights Potency of Adjuvant Nivolumab in Melanoma

September 27th 2018

Jeffrey S. Weber, MD, PhD, discusses the promise of nivolumab in this setting and a general overview of the melanoma treatment landscape.

Entinostat/Pembrolizumab Combo Shows Promise in NSCLC Subgroup

September 26th 2018

Ongoing analyses suggest enhanced clinical benefit is derived from the combined use of entinostat and pembrolizumab in a subgroup of patients with PD-1/PD-L1–refractory non–small cell lung cancer who have high levels of peripheral blood monocytes.

Atezolizumab Prolongs Survival in SCLC

September 26th 2018

The addition of atezolizumab to standard carboplatin and etoposide in the frontline setting significantly prolonged survival in patients with extensive-stage small cell lung cancer compared with the chemotherapy regimen alone.

Adding Durvalumab to Chemoradiation Improves OS in Unresectable Stage III NSCLC

September 25th 2018

Durvalumab induced a clinically meaningful improvement in overall survival compared with placebo in patients with stage III, unresectable non–small cell lung cancer who have not progressed following chemoradiotherapy.